RESUMEN
Background: In dogs undergoing vertebral column stabilization, post-operative computed tomography (CT) evaluates implant placement. The impact on the interpretation of metallic artifact associated with titanium implants in dogs remains to be established. Our objective was to quantify metallic artifact on CT associated with titanium pedicle screws. Methods: The study design included an in vitro model and a retrospective review of 11 dogs with vertebral column stabilization. Twenty four titanium pedicle screws (6 each: 2.0 mm, 2.7 mm, 3.5 mm, and 4.5 mm) were inserted into a 20% ballistic gel, and CT scan of the construct was performed. Three blinded raters used a bone window to measure the maximum width (effective size) of each screw, one rater measured effective size using an ultrawide window and 45 titanium pedicle screws (3×2.0 mm, 5×2.7 mm, 30×3.5 mm, and 7×4.5 mm) in 11 clinical cases. Effective size measurements were compared to actual screw sizes. Results: The effective size was 26.9-43.8%, 9.2-18.5%, and 21.1-30.5% larger than the actual size for the in vitro system (bone window), in vitro system (ultrawide window), and clinical cases, respectively. The mean gross difference for the in vitro measurements varied by implant size (p < 0.001) and was positively correlated with implant size (r = 0.846), but the mean percentage difference was negatively correlated with implant size (p < 0.001). Overestimation was larger for the in vitro model bone window compared to the ultrawide window (p < 0.001) and clinical cases (p = 0.001). Conclusion: Metallic artifact associated with titanium pedicle screws on CT resulted in an overestimation of screw size. This information might aid in the interpretation of implant placement on post-operative imaging.
RESUMEN
The objective of this study was to describe the pharmacokinetics (PK) of cytarabine (CA) after subcutaneous (SC) administration to dogs with meningoencephalomyelitis of unknown etiology (MUE). Twelve dogs received a single SC dose of CA at 50 mg/m2 as part of treatment of MUE. A sparse sampling technique was used to collect four blood samples from each dog from 0 to 360 min after administration. All dogs were concurrently receiving prednisone (0.5-2 mg kg-1 day-1 ). Plasma CA concentrations were measured by HPLC, and pharmacokinetic parameters were estimated using nonlinear mixed-effects modeling (NLME). Plasma drug concentrations ranged from 0.05 to 2.8 µg/ml. The population estimate (CV%) for elimination half-life and Tmax of cytarabine in dogs was 1.09 (21.93) hr and 0.55 (51.03) hr, respectively. The volume of distribution per fraction absorbed was 976.31 (10.85%) ml/kg. Mean plasma concentration of CA for all dogs was above 1.0 µg/ml at the 30-, 60-, 90-, and 120-min time points. In this study, the pharmacokinetics of CA in dogs with MUE after a single 50 mg/m2 SC injection in dogs was similar to what has been previously reported in healthy beagles; there was moderate variability in the population estimates in this clinical population of dogs.
Asunto(s)
Antimetabolitos Antineoplásicos/farmacocinética , Citarabina/farmacocinética , Enfermedades de los Perros/tratamiento farmacológico , Encefalomielitis/veterinaria , Inmunosupresores/farmacocinética , Meningoencefalitis/veterinaria , Prednisona/farmacocinética , Animales , Antimetabolitos Antineoplásicos/administración & dosificación , Antimetabolitos Antineoplásicos/sangre , Antimetabolitos Antineoplásicos/uso terapéutico , Citarabina/administración & dosificación , Citarabina/sangre , Citarabina/uso terapéutico , Perros , Combinación de Medicamentos , Encefalomielitis/tratamiento farmacológico , Femenino , Inmunosupresores/administración & dosificación , Inmunosupresores/sangre , Inmunosupresores/uso terapéutico , Inyecciones Subcutáneas , Masculino , Meningoencefalitis/tratamiento farmacológico , Prednisona/administración & dosificación , Prednisona/sangre , Prednisona/uso terapéuticoRESUMEN
BACKGROUND: Progressive myelomalacia (PMM) is a catastrophic disease associated with acute intervertebral disc extrusion (IVDE). Published data on the clinical characteristics of this disease are limited. OBJECTIVE: To describe the onset and progression of clinical signs of PMM in a large case cohort. ANIMALS: Fifty-one dogs, 18 with histopathologically confirmed PMM, 33 presumptively diagnosed based on clinical signs and diagnostic imaging. METHODS: Retrospective study. Dogs with confirmed IVDE and either a histopathologic diagnosis of PMM or a high clinical suspicion were identified by medical record search. Data on nature and progression of signs were extracted. RESULTS: Twenty-four of 51 dogs were Dachshunds. T12-T13 was the most common site of disc extrusion (12 of 56), and 18 of 55 of mid-to-caudal lumbar discs (between L3 and L6) were affected. Onset of PMM signs ranged from present at first evaluation (17/51) to 5 days after presentation, with 25 of 51 cases developing signs within 48 hours. Progression of signs from onset of PMM to euthanasia or death, excluding 7 cases euthanized at presentation, ranged from 1 to 13 days with 23 being euthanized within 3 days. Nonspecific systemic signs were documented in 30 of 51 dogs. CONCLUSION AND CLINICAL IMPORTANCE: The majority of dogs developed PMM within 2 days of presentation and was euthanized within another 3 days. However, onset can be delayed up to 5 days after presentation with progression to euthanasia taking as long as 2 weeks. Mid-to-caudal lumbar discs might be associated with an increased risk of PMM.
Asunto(s)
Enfermedades de los Perros/patología , Degeneración del Disco Intervertebral/veterinaria , Desplazamiento del Disco Intervertebral/veterinaria , Enfermedades de la Médula Espinal/veterinaria , Animales , Progresión de la Enfermedad , Enfermedades de los Perros/diagnóstico por imagen , Perros , Femenino , Degeneración del Disco Intervertebral/diagnóstico por imagen , Degeneración del Disco Intervertebral/patología , Desplazamiento del Disco Intervertebral/diagnóstico por imagen , Desplazamiento del Disco Intervertebral/patología , Imagen por Resonancia Magnética/veterinaria , Masculino , Mielografía/veterinaria , Estudios Retrospectivos , Enfermedades de la Médula Espinal/mortalidad , Enfermedades de la Médula Espinal/patología , Tomografía Computarizada por Rayos X/veterinariaRESUMEN
BACKGROUND: Outcome of acute experimental spinal cord injury is strongly associated with tissue perfusion and oxygenation. Cardiopulmonary depression could affect outcome in dogs undergoing general anesthesia for surgical treatment of thoracolumbar intervertebral disk extrusion (IVDE). HYPOTHESIS/OBJECTIVES: To evaluate the effects of general anesthesia on functional outcome in dogs undergoing surgery to treat thoracolumbar IVDE. ANIMALS: Eighty-four client-owned dogs with acute thoracolumbar IVDE treated by decompressive hemilaminectomy. METHODS: Exploratory, retrospective observational study. Medical records were reviewed for clinical presentation and anesthetic monitoring variables, including duration of anesthesia and surgery, hypotension, bradycardia, temperature, and respiratory parameters. Multivariable regression tree analysis was performed to explore associations between anesthetic variables and functional outcome scores after 6 weeks, as well as return to ambulatory status. RESULTS: Episodes of bradycardia (69%) and hypotension (57%) were frequent. Across all outcome measures, regression tree analysis highlighted functional grade at presentation as the primary determining factor, and among pain perception negative dogs, there was a possible association between increased duration of surgery and poorer outcome. In dogs with intact pain perception, duration of bradycardia, mean body temperature, and mean end-tidal carbon dioxide were highlighted. CONCLUSIONS AND CLINICAL IMPORTANCE: Exploratory statistical methods can facilitate hypothesis-generating studies to inform prospective investigations in veterinary medicine. Although the mechanism is uncertain, increased duration of surgery might be associated with poorer outcome in pain perception negative dogs with thoracolumbar IVDE.
Asunto(s)
Anestesia General/veterinaria , Descompresión Quirúrgica/veterinaria , Enfermedades de los Perros/cirugía , Desplazamiento del Disco Intervertebral/veterinaria , Laminectomía/veterinaria , Anestesia General/efectos adversos , Anestesia General/métodos , Animales , Bradicardia/inducido químicamente , Bradicardia/veterinaria , Descompresión Quirúrgica/métodos , Perros , Femenino , Hipotensión/inducido químicamente , Hipotensión/veterinaria , Desplazamiento del Disco Intervertebral/cirugía , Laminectomía/métodos , Masculino , Estudios Retrospectivos , Vértebras Torácicas/cirugía , Resultado del TratamientoRESUMEN
BACKGROUND: Dogs with spinal cord injury are at increased risk of developing bacteriuria due to increased residual urine volume. Cranberry extract inhibits binding of E. coli to uroepithelial cells, potentially reducing risk of bacteriuria. HYPOTHESIS: Cranberry extract reduces risk of bacteriuria in dogs after acute TL-IVDH. ANIMALS: Client-owned dogs with acute onset TL-IVDH causing nonambulatory status. METHODS: Randomized, placebo-controlled, blinded, prospective clinical trial. Dogs with acute TL-IVDH were recruited 48 hours postoperatively and randomized to receive cranberry extract or placebo in a masked fashion. Urine cultures and neurological examinations were performed 2, 4, and 6 weeks postoperatively. The number of dogs with bacteriuria (all bacterial species) and bacteriuria (E. coli) were primary and secondary outcome measures and were evaluated using chi-squared test. Urine antiadhesion activity (AAA) was measured in a subset (N = 47) and examined in a secondary analysis evaluating additional risk factors for bacteriuria. RESULTS: Bacteriuria was detected 17 times in 94 dogs (6 placebo, 11 cranberry, P = .12). There were 7 E. coli. positive cultures (1 placebo, 6 cranberry, P = .09). Dogs in both groups had positive urine AAA (14/21: placebo, 16/26: cranberry), and dogs with urine AAA had significantly fewer E. coli positive cultures (n = 1) than dogs without it (n = 4) (P = .047). CONCLUSIONS AND CLINICAL IMPORTANCE: This clinical trial did not show a benefit of oral cranberry extract but had low power. Cranberry extract supplementation did not impact urine AAA, but a possible association between urine AAA and lower risk of E. coli bacteriuria was identified. Other doses could be investigated.
Asunto(s)
Enfermedades de los Perros/tratamiento farmacológico , Desplazamiento del Disco Intervertebral/veterinaria , Extractos Vegetales/uso terapéutico , Vértebras Torácicas , Infecciones Urinarias/veterinaria , Vaccinium macrocarpon , Administración Oral , Animales , Antiinfecciosos/administración & dosificación , Antiinfecciosos/uso terapéutico , Bacteriuria/complicaciones , Bacteriuria/tratamiento farmacológico , Bacteriuria/orina , Bacteriuria/veterinaria , Perros , Femenino , Desplazamiento del Disco Intervertebral/complicaciones , Masculino , Extractos Vegetales/administración & dosificación , Estudios Prospectivos , Método Simple Ciego , Resultado del Tratamiento , Infecciones Urinarias/complicaciones , Infecciones Urinarias/tratamiento farmacológico , Infecciones Urinarias/orinaRESUMEN
The objective of this study was to evaluate the plasma and serum concentrations of cytarabine (CA) administered via constant rate infusion (CRI) in dogs with meningoencephalomyelitis of unknown etiology (MUE). Nineteen client-owned dogs received a CRI of CA at a dose of 25 mg/m2 /h for 8 h as treatment for MUE. Dogs were divided into four groups, those receiving CA alone and those receiving CA in conjunction with other drugs. Blood samples were collected at 0, 1, 8, and 12 h after initiating the CRI. Plasma (n = 13) and serum (n = 11) cytarabine concentrations were measured by high-pressure liquid chromatography. The mean peak concentration (CMAX ) and area under the curve (AUC) after CRI administration were 1.70 ± 0.66 µg/mL and 11.39 ± 3.37 h·µg/mL, respectively, for dogs receiving cytarabine alone, 2.36 ± 0.35 µg/mL and 16.91 + 3.60 h·µg/mL for dogs administered cytarabine and concurrently on other drugs. Mean concentrations for all dogs were above 1.0 µg/mL at both the 1- and 8-h time points. The steady-state achieved with cytarabine CRI produces a consistent and prolonged exposure in plasma and serum, which is likely to produce equilibrium between blood and the central nervous system in dogs with a clinical diagnosis of MUE. Other medications commonly used to treat MUE do not appear to alter CA concentrations in serum and plasma.
Asunto(s)
Citarabina/farmacocinética , Enfermedades de los Perros/tratamiento farmacológico , Encefalomielitis/veterinaria , Infusiones Intravenosas/veterinaria , Animales , Área Bajo la Curva , Citarabina/administración & dosificación , Enfermedades de los Perros/sangre , Perros , Encefalomielitis/sangre , Encefalomielitis/tratamiento farmacológicoRESUMEN
BACKGROUND: Quantification of brain herniation on MRI and its immediate clinical implications are poorly described. OBJECTIVES: Define the normal position of caudal fossa structures on brain MRIs in dogs and cats utilizing morphometry, compare this to dogs and cats with caudal transtentorial herniation (CTH), foramen magnum herniation (FMH) or both identified on MRI, and investigate associations between herniation severity, clinical signs, and 24-hour outcome. ANIMALS: Ninety-two controls (66 dogs, 26 cats), 119 cases with herniation (88 dogs, 31 cats). METHODS: Retrospective case series. The MRI database was searched for controls with normal brain anatomy and cases with brain herniation. Morphometry in controls established TTX (transtentorial to rostroventral cerebellum) to quantify CTH and FMX (caudoventral cerebellum to foramen magnum) to quantify FMH. Measurements were compared between cases and controls. Correlations with specific clinical variables and outcome were investigated. RESULTS: Measurements in medium/large control dogs versus small dog and cat controls were significantly different (P < .001, TTX: -0.46, -0.305, -0.3, FMX: 0.695, 0.27, 0.25, respectively). 119/1564 (7.6%) cases that underwent brain imaging had brain herniation. TTX and FMX were significantly different between controls and cases with CTH or FMH (P < .001). 67/89 (75%) cases with supratentorial lesions had no signs directly attributable to herniation. 71/119 (60%) had a normal anesthetic recovery. TTX was significantly associated with 24-hour survival (P < .001). CONCLUSIONS AND CLINICAL IMPORTANCE: Brain herniation can be quantified on MRI. Clinical signs directly attributable to brain herniation commonly are absent, and more severe CTH based on TTX is associated with a worse short-term outcome.
Asunto(s)
Encéfalo/diagnóstico por imagen , Enfermedades de los Gatos/diagnóstico por imagen , Enfermedades de los Perros/diagnóstico por imagen , Imagen por Resonancia Magnética/veterinaria , Animales , Tamaño Corporal , Encéfalo/patología , Enfermedades de los Gatos/patología , Gatos , Enfermedades de los Perros/patología , Perros , Estudios RetrospectivosRESUMEN
OBJECTIVES: Acute intervertebral disc herniation is commonly managed by veterinary neurologists and surgeons. Anecdote suggests that patterns of management vary considerably and there is controversy surrounding many aspects of treatment. The goal of this study was to document patterns in management of acute spinal cord injury caused by acute intervertebral disc herniation among these two groups to aid in future discussions on best practices. METHODS: A survey querying diagnostic, medical and surgical practices for dogs with acute intervertebral disc herniation was distributed to diplomates on the databases of the American College of Veterinary Surgeons and the American College of Veterinary Internal Medicine (Neurology). RESULTS: Responses were received from 314 board-certified veterinary surgeons and neurologists. Both groups handled timing of decompression, surgical approach, and most postoperative recommendations in a similar fashion. Case volume differed between groups, with 77% of neurologists and 18% of surgeons managing ê50 cases of acute intervertebral disc herniation per year. MRI was used most frequently as a diagnostic tool by neurologists (75%), while CT was used most commonly by surgeons (58%). Corticosteroids were routinely administered as a neuroprotective strategy by 34% of surgeons and 11% of neurologists. Disc fenestration was performed "always" or "most of the time" by 69% of neurologists and 36% of surgeons. CLINICAL IMPORTANCE: Understanding the common practices in the management of canine acute intervertebral disc herniation can provide a springboard for future discussions regarding the best practices in diagnosing and treating this disease.
Asunto(s)
Enfermedades de los Perros/cirugía , Desplazamiento del Disco Intervertebral/veterinaria , Pautas de la Práctica en Medicina/estadística & datos numéricos , Animales , Canadá , Discectomía/veterinaria , Enfermedades de los Perros/diagnóstico por imagen , Perros , Femenino , Humanos , Desplazamiento del Disco Intervertebral/cirugía , Vértebras Lumbares/diagnóstico por imagen , Vértebras Lumbares/cirugía , Masculino , Radiografía/veterinaria , Encuestas y Cuestionarios , Estados Unidos , Medicina Veterinaria/estadística & datos numéricosRESUMEN
Prospective data on the recovery of coordination in dogs suffering acute thoracolumbar intervertebral disc herniations (TL-IVDH) are limited. The purpose of this study was to use treadmill based and open field scores (OFS) to quantify recovery of stepping ability and forelimb, hindlimb coordination in the 6 weeks following surgical decompression of dogs with TL-IVDH. Sixty-three dogs were grouped at presentation as grades 3 (non-ambulatory paraparetic), 4 (paraplegic) or 5 (paraplegic without pain sensation) and were evaluated 2, 4, and 6 weeks post-operatively. Stepping scores and Regularity Index (RI), a measure of coordination, were calculated from treadmill walking, and an OFS incorporating supported and unsupported walking was assigned. Outcomes for the three measures were compared between groups and correlation between scoring methods was assessed. Grade 3 and 4 dogs recovered ambulation by 2 weeks, reaching median stepping scores of 96 and 90% by 6 weeks, respectively. Recovery of coordination differed between groups 3 and 4 with median RI scores of 93.9% and 63%, respectively, by 6 weeks. Eight grade 5 dogs failed to recover independent ambulation by 6 weeks. Nine dogs recovered with scores that were significantly worse than the grade 3 and 4 dogs at 6 weeks for stepping score (P < 0.001) and RI (P < 0.001). OFS correlated closely with stepping and RI scores and each group was significantly different using this ordinal scale. In conclusion, recovery of coordination was incomplete in dogs that showed good recovery of stepping. The data generated could be used for clinical trial design.
Asunto(s)
Enfermedades de los Perros/cirugía , Desplazamiento del Disco Intervertebral/veterinaria , Disco Intervertebral/cirugía , Traumatismos de la Médula Espinal/veterinaria , Caminata , Enfermedad Aguda , Animales , Enfermedades de los Perros/etiología , Perros , Femenino , Miembro Anterior/fisiología , Miembro Posterior/fisiología , Disco Intervertebral/patología , Desplazamiento del Disco Intervertebral/etiología , Desplazamiento del Disco Intervertebral/cirugía , Masculino , Estudios Prospectivos , Traumatismos de la Médula Espinal/etiología , Traumatismos de la Médula Espinal/cirugíaRESUMEN
BACKGROUND: Acute intervertebral disk herniation (IVDH) is a common cause of spinal cord injury in dogs and currently there is no proven medical treatment to counter secondary injury effects. Use of methylprednisolone sodium succinate (MPSS) or polyethylene glycol (PEG) as neuroprotectants is advocated but controversial because neither treatment has been tested in placebo-controlled, randomized, blinded trials in dogs. HYPOTHESIS: Polyethylene glycol will improve the outcome of severe spinal cord injury caused by IVDH compared to MPSS or placebo. ANIMALS: Client-owned dogs with acute onset of thoracolumbar IVDH causing paralysis and loss of nociception for <24 hours. METHODS: Dogs were randomized to receive MPSS, PEG, or placebo; drugs appeared identical and group allocation was masked. Drug administration was initiated once the diagnosis of IVDH was confirmed and all dogs underwent hemilaminectomy. Neurologic function was assessed 2, 4, 8, and 12 weeks postoperatively using an open field gait score (OFS) as the primary outcome measure. Outcomes were compared by the Wilcoxon rank sum test. RESULTS: Sixty-three dogs were recruited and 47.6% recovered ambulation. 17.5% developed progressive myelomalacia but there was no association with group. There was no difference in OFS among groups. Although full study power was not reached, conditional power analyses indicated the futility of continued case recruitment. CONCLUSIONS: This clinical trial did not show a benefit of either MPSS or PEG in the treatment of acute, severe thoracolumbar IVDH when used as adjunctive medical treatment administered to dogs presenting within 24 hours of onset of paralysis.
Asunto(s)
Antiinflamatorios/uso terapéutico , Enfermedades de los Perros/tratamiento farmacológico , Desplazamiento del Disco Intervertebral/veterinaria , Hemisuccinato de Metilprednisolona/uso terapéutico , Polietilenglicoles/uso terapéutico , Animales , Antiinflamatorios/administración & dosificación , Perros , Femenino , Desplazamiento del Disco Intervertebral/tratamiento farmacológico , Masculino , Hemisuccinato de Metilprednisolona/administración & dosificación , Nocicepción/efectos de los fármacos , Polietilenglicoles/administración & dosificaciónRESUMEN
This crossover study compared the pharmacokinetics of cytarabine in six healthy dogs following intravenous constant rate infusion (CRI) and subcutaneous (SC) administrations, as these are two routes of administration commonly employed in the treatment of meningoencephalitis of unknown etiology. Each dog received a SC cytarabine injection of 50 mg/m(2) or an 8 h CRI of 25 mg/m(2) per hour, with a 7-day washout before receiving the alternative treatment. Blood samples were collected for 16 h after CRI initiation and for 8 h after SC injection. Plasma concentrations were measured by high-pressure liquid chromatography (HPLC). Pharmacokinetic parameters were estimated using the best-fit compartmental analysis for both CRI and SC routes. Terminal half-life (T(1/2) ) of cytarabine was 1.35 ± 0.3 and 1.15 ± 0.13 h after SC administration and CRI, respectively. Mean peak concentration (Cmax ) was 2.88 and 2.80 µg/mL for SC and CRI administration, respectively. Volume of distribution was 0.66 ± 0.07 l/kg. The 8-h CRI produced steady-state plasma concentrations as determined by consecutive measurement that did not decline until the end of the infusion. The SC administration did not achieve steady-state concentrations because cytarabine administered by this route was rapidly absorbed and eliminated quickly. The steady state achieved with the cytarabine CRI may produce a more prolonged exposure of cytarabine at cytotoxic levels in plasma compared to the concentrations after SC administration.
Asunto(s)
Antimetabolitos Antineoplásicos/farmacocinética , Citarabina/farmacocinética , Perros/metabolismo , Animales , Antimetabolitos Antineoplásicos/administración & dosificación , Antimetabolitos Antineoplásicos/sangre , Área Bajo la Curva , Estudios Cruzados , Citarabina/administración & dosificación , Citarabina/sangre , Perros/sangre , Semivida , Infusiones Intravenosas/veterinaria , Inyecciones Subcutáneas/veterinariaRESUMEN
BACKGROUND: There is little evidence-based information available to guide treatment of refractory epilepsy in dogs. The antiepileptic drug levetiracetam (LEV) is administered to dogs, although its safety and efficacy are unknown. OBJECTIVE: To evaluate the safety and efficacy of LEV as adjunctive therapy for refractory epilepsy in dogs. ANIMALS: Thirty-four client-owned dogs with idiopathic epilepsy. METHODS: Randomized, blinded trial involving dogs resistant to phenobarbital and bromide. Dogs received LEV (20 mg/kg PO q8h) or placebo for 16 weeks, and after a 4-week washout were crossed over to the alternate treatment for 16 weeks. Owners kept records on seizure frequency and adverse events. Hemogram, chemistry profile, urinalysis, and serum antiepileptic drug concentrations were evaluated at established intervals. RESULTS: Twenty-two (65%) dogs completed the study. Weekly seizure frequency during the 1st treatment period decreased significantly during LEV administration relative to baseline (1.9 ± 1.9 to 1.1 ± 1.3, P = .015). The reduction in seizures with LEV was not significant when compared to placebo (1.1 ± 1.3 versus 1.5 ± 1.7, P = .310). The most common adverse event was ataxia, with no difference in incidence between LEV and placebo (45 versus 18%, P = .090). No changes in laboratory parameters were identified and owners reported an improved quality of life (QOL) with LEV compared to placebo (QOL score 32.7 ± 4.3 versus 29.4 ± 4.5, P = .028). CONCLUSIONS AND CLINICAL IMPORTANCE: Adjunctive treatment with LEV appears safe in epileptic dogs. Efficacy of LEV over placebo was not demonstrated, although the power of the study was limited. Further evaluation of LEV as treatment for epilepsy in dogs is warranted.
Asunto(s)
Anticonvulsivantes/administración & dosificación , Enfermedades de los Perros/tratamiento farmacológico , Epilepsia/veterinaria , Piracetam/análogos & derivados , Convulsiones/veterinaria , Animales , Anticonvulsivantes/efectos adversos , Anticonvulsivantes/sangre , Estudios Cruzados , Enfermedades de los Perros/sangre , Perros , Método Doble Ciego , Epilepsia/sangre , Epilepsia/tratamiento farmacológico , Femenino , Levetiracetam , Masculino , Piracetam/administración & dosificación , Piracetam/efectos adversos , Piracetam/sangre , Calidad de Vida , Convulsiones/sangre , Convulsiones/tratamiento farmacológico , Estadísticas no ParamétricasRESUMEN
The purpose of this paper is to follow the course of historical development in the use of radiopharmaceuticals as a diagnostic tool in nuclear medicine. This course has been a series of plateaus and growth spurts throughout its history. This article is designed to identify the different phases of the development of nuclear medicine, pointing out the events which most shaped its history along the way. Those events included such things as the discovery of radioactivity, the development of the cyclotron and nuclear reactor as a method of producing high specific activity radioactive material, the development of imaging equipment such as the rectilinear scanner, scintillation camera, PET and SPECT, the application of computers, and the discovery of 99mTc and the development of associated kits designed to image many organs and processes in the human body.
Asunto(s)
Medicina Nuclear/historia , Radioisótopos , Historia del Siglo XX , Humanos , Radioisótopos de Yodo , Medicina Nuclear/instrumentación , Radioisótopos de Fósforo , Radioinmunoensayo/historia , Conteo por Cintilación/historia , Conteo por Cintilación/instrumentación , Radioisótopos de Estroncio , Tecnecio , Tomografía Computarizada de Emisión/historiaRESUMEN
The purpose of this paper is to follow the course of historical development in the use of radiopharmaceuticals as a therapeutic tool in nuclear medicine. This chapter is designed to point out the different phases of the development of therapeutic nuclear medicine, pointing out the events which most shaped its history along the way. Those events included the discovery of radioactivity, the development of the cyclotron and nuclear reactor as a method of delivering high specific activity radioactive sources, and a few significant therapeutic radionuclides such as 131I and 32P. The most significant therapeutic radionuclide was radium, which is treated very extensively in this paper from an historical viewpoint. It is only recently that attention of the nuclear medicine community turned to new therapeutic agents, such as bone pain palliation agents, monoclonal antibodies, and others. It may be that the next growth phase of nuclear medicine will revolve around therapy with these radionuclides.
Asunto(s)
Medicina Nuclear/historia , Radioisótopos/uso terapéutico , Radioterapia/historia , Braquiterapia/historia , Historia del Siglo XIX , Historia del Siglo XX , Humanos , Neoplasias/radioterapia , Radio (Elemento)/uso terapéutico , Radón/uso terapéuticoRESUMEN
The use of radionuclides in therapy, both as sealed sources and in the radiopharmaceutical form, is discussed from receipt of radiopharmaceuticals through their use, to their disposal. The licensing requirements for use of therapeutic radionuclides is presented. Discussions dealing with receipt, storage and administration of radiopharmaceuticals are treated in detail, as well as suggestions for personnel monitoring. Procedures involved in the event of emergency surgery and/or death are discussed. The misadministration rules of the Nuclear Regulatory Commission regarding therapies were presented.